Prescription Psychedelics: The Road from FDA Approval to Clinical Practice
- 20 August 2021
- journal article
- editorial
- Published by Elsevier BV in The American Journal of Medicine
- Vol. 135 (1), 15-16
- https://doi.org/10.1016/j.amjmed.2021.07.033
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 studyNature Medicine, 2021
- Trial of Psilocybin versus Escitalopram for DepressionThe New England Journal of Medicine, 2021
- The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSDPLOS ONE, 2020
- Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months laterJournal of Psychopharmacology, 2008